International Journal of Drug Delivery Technology
Volume 15, Issue 3

Formulation, Development and Evaluation of Memantine and Memantine-Curcumin Co-loaded Liposomes for Intranasal Delivery in Alzheimer's

Abhish Jadhav*, Mrudula Bele

Department of Pharmaceutics, NDMVP’s College of Pharmacy, Nasik-422005, Maharashtra, India

Received: 15th Jun, 2025; Revised: 28th Jul, 2025; Accepted: 17th Aug, 2025; Available Online: 25th Sep, 2025 

ABSTRACT

Creation of amyloid β (Aβ) peptides involved in disease progression is the important pathway in Alzheimer’s disease (AD) progression and that is a crucial target for the treatment of AD. NMDA receptor antagonists have emerged as a promising strategy to lower Aβ levels and slow AD development. However, because the blood-brain barrier (BBB) is so restrictive, their efficacy is restricted when administered systemically. In AD, inflammation, oxidative stress, and the buildup of abnormal proteins like amyloid and tau are common and recent research suggests use of curcumin may help counteract these damaging processes and protect neurons. Unfortunately, both NMDA receptor antagonists and curcumin face challenges crossing the BBB, resulting in poor brain uptake. The nose-to-brain (NtB) delivery route offers a potential solution by bypassing the BBB and allowing direct access to the brain. Liposomal drug delivery systems enhances drug reach by improving efficient transport to the brain as well as greater drug stability. This study used the rotary evaporation method to prepare memantine liposomes and coupled memantine-curcumin liposomes, which were then evaluated In-vitro. The findings indicate that liposomal formulations of memantine and memantine-curcumin can promote effective intracellular drug delivery, potentially cross tight junctions in the BBB, and may help reduce amyloid plaque formation and inflammation, highlighting their promise as an AD treatment via NtB delivery having good physicochemical properties and stability of drug.

Keywords: Alzheimer's disease, Memantine hydrochloride, Curcumin, Liposomes, Nose-to-brain delivery, QbD approach.

How to cite this article: Abhish Jadhav, Mrudula Bele. Formulation, Development and Evaluation of Memantine and Memantine-Curcumin Co-Loaded Liposomes for Intranasal Delivery in Alzheimer's. International Journal of Drug Delivery Technology. 2025;15(3):1205-11. doi: 10.25258/ijddt.15.3.40

REFERENCES

  1. Neugroschl J, Wang S. Alzheimer’s disease: diagnosis and treatment across the spectrum of disease severity. Mount Sinai journal of medicine, New York. 2011 Jul;78(4):596-612. https://doi.org/10.1002/msj.20279
  2. Regelin AE, Fankhaenel S, Gürtesch L, Prinz C, von Kiedrowski G, Massing U. Biophysical and lipofection studies of DOTAP analogs. Biochimica et biophysica acta. 2000 Mar 15;1464(1):151-64. https://doi.org/10.1016/S0005-2736(00)00126-7
  3. Bloom GS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA neurology. 2014 Apr 1;71(4):505-8. https://doi.org/10.1001/jamaneurol.2013.5847
  4. Dislich B, Lichtenthaler SF. The membrane-bound aspartyl protease BACE1: molecular and functional properties in Alzheimer’s disease and beyond. Frontiers in physiology. 2012 Feb 17;3:8. https://doi.org/10.3389/fphys.2012.00008
  5. Lee D, Minko T. Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier. Pharmaceutics. 2021 Nov 30;13(12):2049. https://doi.org/10.3390/pharmaceutics13122049
  6. Peron R, Vatanabe IP, Manzine PR, Camins A, Cominetti MR. Alpha-secretase ADAM10 regulation: insights into Alzheimer’s disease treatment. Pharmaceuticals. 2018 Jan 29;11(1):12. https://doi.org/10.3390/ph11010012
  7. Deuss M, Reiss K, Hartmann D. Part-time α-secretases: the functional biology of ADAM 9. Current Alzheimer research. 2008 Apr 1;5(2):187-201. https://doi.org/10.2174/156720508783954686
  8. Chasseigneaux S, Allinquant B. Functions of Aβ, sAPPα and sAPPβ: similarities and differences. Journal of neurochemistry. 2012 Jan;120 (Supplement 1):99-108. https://doi.org/10.1111/j.1471-4159.2011.07584.x
  9. Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ, Le Guen M, Fischler M, Devillier P. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacology and therapeutics. 2012 Jun 1;134(3):366-79. https://doi. https://doi.org/10.1016/j.pharmthera.2012.03.003
  10. Maia MA, Sousa E. BACE-1 and γ-secretase as therapeutic targets for Alzheimer’s disease. Pharmaceuticals. 2019 Mar 19;12(1):41. https://doi.org/10.3390/ph12010041
  11. Singh B, Day CM, Abdella S, Garg S. Alzheimer’s disease current therapies, novel drug delivery systems and future directions for better disease management. Journal of controlled release. 2024 Mar 1;367:402-24. https://doi.org/10.1016/j.jconrel.2024.01.047
  12. Garodia P, Hegde M, Kunnumakkara AB, Aggarwal BB. Curcumin, inflammation, and neurological disorders: how are they linked? Integrative medicine research. 2023 Sep 1;12(3):100968. https://doi.org/10.1016/j.imr.2023.100968
  13. Hong SS, Oh KT, Choi HG, Lim SJ. Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives. Pharmaceutics. 2019 Oct 17;11(10):540. https://doi.org/10.3390/pharmaceutics11100540
  14. Schofield T, Robbins D, Miró-Quesada G. Critical quality attributes, specifications, and control strategy, Quality by Design for Biopharmaceutical Drug Product Development. (edited by: F Jameel, S Hershenson, MA Khan & S Martin-Moe). Springer New York: New York, NY. 2015:511-35. https://doi.org/10.1007/978-1-4939-2316-8_21
  15. Dhoble S, Patravale V. Development of anti-angiogenic erlotinib liposomal formulation for pulmonary hypertension: a QbD approach. Drug delivery and translational research. 2019 Oct;9(5):980-96. https://doi.org/10.1007/s13346-019-00641-2